Teva: ‘We Have To Overachieve To Get Back Our Credibility’

CEO Francis Bullish, As Share Price Climbs High Ahead Of Two-Year Anniversary

Teva’s CEO Richard Francis has spoken candidly about the steps he has taken in order for Teva to reclaim its credibility, underpinned by the company’s ‘Pivot to Growth’ strategy.

SC1807_Market Growth_572387551_1200.jpg
• Source: Shutterstock

Teva feels its present and its recent past will be “valued far more than the distant past,” as its leader admitted the company was continuing to battle to regain “credibility” following years of stagnation and decline.

Appearing at the recent Sidley Healthcare Investment Conference 2024 in central London, the Israeli firm’s CEO, Richard Francis, was asked...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

BC Partners Bids For Biogaran Buyout – But Will It Face French Pushback?

 
• By 

Private equity firm BC Partners has revealed that it is in exclusive negotiations to acquire Servier’s French generics and biosimilars business Biogaran. But with France’s government having expressed opposition to the sale, could there be strings attached?

Roche Braces For Late 2026 Biosimilar Wave

 
• By 

Roche expects biosimilars to Perjeta and Xolair by the end of 2026, marking a key inflection point for two of its major franchises. Shanghai Henlius Biotech leads development for pertuzumab, while Celltrion is positioned as the frontrunner for omalizumab.

Sandoz Strikes $300m Deal With Just-Evotec For French Biosimilars Site

 
• By 

Sandoz has made yet another major move to further bolster its booming biosimilars business, striking a $300m deal to acquire outright a French development and manufacturing facility from existing biosimilars partner Just-Evotec Biologics.

Generics Bulletin’s Top 50 Ranking For 2025

 
• By 

This article compiles all of the data from Generics Bulletin’s 2025 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.

More from Business

Celltrion Nears Deal For US Biologics Plant To Quell Tariff Concerns

 
• By 

Celltrion is the preferred bidder for the acquisition of a large-scale cGMP biologics manufacturing plant in the US, marking a pivotal move to localize production and secure its US pharmaceutical business against rising tariff risks.

The Generics Bulletin Top 50, Part Three: New Firms Enter Global Grouping

 
• By 

In the third instalment of this year’s Generics Bulletin Top 50, we reveal which firms have entered the ranking for the first time.

Neuraxpharm Targets Asia-Pacific In Latest Phase Of Expansion Beyond Europe

 
• By 

Neuraxpharm has launched its Australian affiliate as part of its continued international expansion beyond Europe. The company will introduce CNS treatments including its acquired Nuvigil, Provigil, and the recently TGA-approved Briumvi for multiple sclerosis.